5e5 of anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Carbonic Anhydrase IX (38-414) Protein, His Tag (Cat. No. CA9-HA2H7) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
2e5 of Anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-Carbonic Anhydrase IX Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) with a linear range of 0.01-1.25 μg/mL (QC tested).
The purity of Cynomolgus Carbonic Anhydrase IX Protein, His Tag (Cat. No. CA9-C52H3) is more than 90% and the molecular weight of this protein is around 38-48 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Girentuximab | MAb-G250; cG250; WX-G250 | Phase 3 Clinical | Wilex AG | Kidney Neoplasms; Carcinoma, Renal Cell | Details |
Girentuximab-Zr-89 | 89Zr-TX250; TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TLX250 | Phase 3 Clinical | Wilex AG | Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Contrast agents; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Sarcoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
Lutetium-177 DOTA girentuximab | TLX-250 | Phase 2 Clinical | Wilex AG, Heidelberg, Telix Pharmaceuticals Ltd | Carcinoma, Renal Cell; Neoplasms | Details |
[177Lu]Lu-DPI-4452 | [177Lu]Lu-DPI-4452; Debio 0228; ITM-91 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Debio-0328 | ITM-94D; [68Ga]Ga-DPI-4452; Gallium-68-DPI-4452 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
68Ga-NY104 | 68Ga-NY-104; 68Ga-NYM005 | Phase 2 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Carcinoma, Renal Cell | Details |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular Inc | Neoplasms | Details |
PHC-102 | PHC102; 99mTc-CAIX | Phase 1 Clinical | Philochem | Carcinoma, Renal Cell | Details |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details | |
18F-NY104 | 18F-NY104; 18F-NYM005 | Phase 1 Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Carcinoma, Renal Cell; Contrast agents | Details |
CA9hu-1 | CA9hu-1 | Phase 1 Clinical | Mabpro AS | Head and Neck Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details | |
PD-32766 | PD-32766; 64Cu-PD-32766; 225Ac-PD-32766 | Clinical | PeptiDream Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Glioblastoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms | Details |
This web search service is supported by Google Inc.